Biden wants more nurses in nursing homes but might need Medicaid boost azcentral.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from azcentral.com Daily Mail and Mail on Sunday newspapers.
Agency: " Centers for Medicare& Medicaid Services, Department of Health and Human Services." This final rule finalizes certain 2021 and 2022 Star Ratings provisions that were included in two interim final rules with comment period that CMS issued on April 6, 2020, and September 2, 2020; other policies from those interim final rules will be addressed in other.
FRONTLINE, NPR and American University s Investigative Reporting Workshop, examines the market forces and uneven government support that are deepening the healthcare divide
Medicaid and CHIP Payment and Access Commission Releases March 2021 Report to Congress
Targeted News Service
March 15, 2021:
March 2021 Report to
Congress on Medicaid and CHIP today, recommending that
Congress adopt measures aimed at improving Medicaid s responsiveness during economic downturns; addressing concerns about high rates of maternal morbidity and mortality; and reexamining Medicaid s estate recovery policies. The report also contains additional topics of interest to
Congress such as integrating care for people who are dually eligible for Medicaid and Medicare, and improving hospital payment policy for the nation s safety net hospitals. This report offers
Congress a number of timely recommendations it can take to improve Medicaid s programmatic response to national challenges related to the COVID-19 pandemic, as well as racial and ethnic disparities in health, said MACPAC Chair
To embed, copy and paste the code into your website or blog:
The American Rescue Plan Act of 2021, the US$1.9 trillion stimulus package expected to be passed by Congress and signed into law by President Biden by March 14, 2021, contains the first drug pricing legislative action being taken under the new Biden administration.
The American Rescue Plan Act of 2021 includes a provision that eliminates the statutory cap on rebates drug manufacturers pay to Medicaid. These rebates act as a discount off the purchase price and eliminating the cap means that drug company discounts paid to Medicaid can rise. Prior to this change, drug manufacturers could have paid up to 100 percent of the Average Manufacturer Price in rebates to state Medicaid programs for Medicaid-covered drugs.